Search
Krystal Biotech Inc
KRYSAdd to Watchlist
352.060USD
+16.870+5.03%
Close 07-27 16:00（ET）Quotes delayed by 15 min
10.28BMarket Cap
45.45P/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-27The current earnings forecast score of Krystal Biotech Inc is 8.62, ranking 91 out of 386 in the Biotechnology & Medical Research industry. The average price target is 218.00, with a high of 255.00 and a low of 198.00.
Analyst Rating
Based on
13
analysts
Buy
Current Rating
353.212
Target Price
+5.38%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
160
Total
6
Median
9
Average
Company name
Ratings
Analysts
Krystal Biotech Inc
KRYS
13
Biogen Inc
BIIB
38
Amgen Inc
AMGN
37
Eli Lilly and Co
LLY
34
AbbVie Inc
ABBV
33
Pfizer Inc
PFE
32
1
2
3
...
32
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Krystal Biotech Inc's expected revenue for the next quarter?
Krystal Biotech Inc's expected revenue is 122.01M.
What is Krystal Biotech Inc's price target?
Analysts forecast that Krystal Biotech Inc's price target is USD 218.00, with the highest forecast at USD 255.00 and the lowest forecast at USD 198.00.
How have Krystal Biotech IncKRYS's recent earnings per share performed?
The market expectation was USD 1.91, while Krystal Biotech IncKRYS's earnings per share (EPS) for the previous quarter was USD 1.77. EPS for the next quarter is expected at USD 1.69.
What is the analyst rating for Krystal Biotech Inc?
Based on the ratings of Krystal Biotech Inc's stock from 13 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.